The PennZone

~ Suvoda and Greenphire, two leading companies in the clinical trial industry, have officially completed their merger. The announcement was made today by Suvoda's Founder and CEO, Jagath Wanninayake.

The merger brings the two companies under common ownership and management, creating a global clinical trial technology company with a comprehensive range of solutions. Suvoda specializes in randomization and trial supply management, consent, and patient outcomes data collection for complex studies. Meanwhile, Greenphire is a leader in clinical trial payments, financial management, and patient support tools.

According to Wanninayake, this partnership marks a significant milestone in their mission to optimize the financial and operational aspects of clinical trials. By combining their expertise and resources, the newly formed company is better equipped to support the urgent and critical moments of clinical trials for their customers.

One of the key benefits of this merger is the expanded set of capabilities that will be available to customers. The combined solutions will be unified on a powerful platform that simplifies workflows and improves the overall experience of running or participating in a clinical trial. This unified data layer will also provide greater insight for sponsors, sites, and patients to make more informed decisions about their trials.

More on The PennZone

• OpenSSL Technical Advisory Committee Elections Now Open – Cast Your Vote
• Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit
• Twitter's Buzzing! What's the Deal with PhotoG, the AI Everyone's Talking About?
• New WHO Mental Health Guidelines Condemn Coercive Psychiatry
• Keenan's Caring Konnections, LLC

The new company will operate under the name Suvoda, which means "the dawn of wellbeing" in Sanskrit. This name reinforces their commitment to easing the patient, site, and sponsor experience in clinical trials while contributing to advancing health globally. However, the name Greenphire will continue at the product level.

Leading software investment firm Thoma Bravo is the lead strategic investor in the combined company. They are joined by Bain Capital Tech Opportunities Fund and LLR Partners as significant minority investors.

Wanninayake expressed his excitement about this new journey together as one firm. He believes that by meeting their customers' evolving needs with enhanced solutions that drive efficiency and reduce costs, they can ultimately improve patient outcomes.

The merger of Suvoda and Greenphire is a significant development in the clinical trial industry, and the newly formed company is poised to make a positive impact on the future of healthcare.

---

Show All News | Report Violation